Galapagos NV

LKFT · NYSE

$31.65+$0.25 (+0.80%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $31.40

LKFT analyst rating

BuyConsensus of 2 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy1
Hold1
Underperform0
Sell0

12-month price target · 10 analysts

Average $35.28 (+11.5% upside)

Low: $21.65
Now: $31.65
High: $53.08

Upgrades and downgrades

The latest rating actions, newest first

LKFT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
RBC Capital	Sep 23, 2026	Upgrade	Sector Perform → Outperform	$26.00 → $45.00	44%
Morgan Stanley	Aug 11, 2026	Maintains	Equal-Weight	$30.00 → $26.00	57%
RBC Capital	Aug 11, 2026	Maintains	Sector Perform	$28.00 → $26.00	44%

The case for and against

Updated Oct 23, 2026

Bull case

Lakefront Biotherapeutics is attractive because its lead asset, gamgertamig, has shown rapid, deep B-cell depletion and a differentiated safety profile in more than 60 autoimmune cytopenia patients, suggesting meaningful efficacy with lower inflammatory risk than CAR-T approaches. The company’s outlook is further supported by a strong balance sheet, limited risk exposure through its GILD partnership, and a negative enterprise value that implies the market is assigning little or no value to the pipeline despite potential annual royalties of up to $885 million from rare autoimmune indications. Near-term dose-ranging data expected by YE-'26 and registrational programs slated for 2027 could de-risk the asset, broaden investor interest, and validate a capital-efficient path to multiple high-value autoimmune opportunities.

Bear case

Lakefront Biotherapeutics is viewed negatively because its valuation depends heavily on unproven pipeline execution, and if GLPG3667 disappoints, is not out-licensed, or fails to attract competitive assets, upside becomes limited while downside remains meaningful. The company also faces a crowded autoimmune landscape, where several BCMAxCD3 bispecifics could pressure future commercial opportunity, and it must still identify dosing that balances CRS risk against durable cell depletion and efficacy. More broadly, its non-revenue-generating status, limited quantitative data for gamgertamig, and uncertainty around future revenues, expenses, and novel-compound toxicity create high fundamental and financial risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.